ARTICLE | Clinical News
Seebri Breezhaler regulatory update
October 8, 2012 7:00 AM UTC
The European Commission approved Seebri Breezhaler glycopyrronium bromide from Novartis as a once-daily, inhaled maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). Th...